原发性骨弥漫性大B细胞淋巴瘤：单中心经验
Primary Diffuse Large B Cell Lymphoma of Bone: A Single-Center Experience.
作者信息
Ayesh Haj Yousef Mahmoud H, Audat Ziad, Al-Shorafat Duha M, Al-Khatib Sohaib, Daoud Ammar K
机构信息
Department of Internal Medicine, Faculty of Medicine, King Abdullah University Hospital, Jordan University of Science and Technology, Irbid, Jordan.
Department of Special Surgery, Faculty of Medicine, King Abdullah University Hospital, Jordan University of Science and Technology, Irbid, Jordan.
出版信息
J Blood Med. 2022 Mar 18;13:143-149. doi: 10.2147/JBM.S350655. eCollection 2022.
BACKGROUND
Primary diffuse large B-cell lymphoma of the bone (PB-DLBCL) is a rare type of extra-nodal lymphoma. This study aimed to examine the clinical characteristics, outcomes, treatment modalities and risk of central nervous system relapse (CNSR) among adult Jordanian patients with PB-DLBCL.
METHODS
This retrospective study included patients aged >16 years who were diagnosed with PB-DLBCL and treated at our hospital between 2002 and 2021. Clinical characteristics, treatment modalities, outcomes and CNSR events were extracted from the hospital's data system and analysed. Patients were categorised into unifocal (UF) and multifocal (MF) PB-DLBCL groups according to the number of bone sites involved. The involvement of only one site was defined as UF, whereas the involvement of two or more sites was defined as MF.
RESULTS
In total, 12 patients were diagnosed with PB-DLBCL. Their median age was 47.5 years (range, 17-80 years). The male:female ratio was 1:1. There were eight patients in the UF PB-DLBCL group and four in the MF PB-DLBCL group. All patients received treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. In the UF PB-DLBCL group, the male:female ratio was 5:3, the median age was 41 years, and the follow-up duration was 9-135 (mean, 83.3) months. In the MF PB-DLBCL group, the male:female ratio was 1:3, the median age was 51.5 years, and the survival time was 3-11 (mean, 7) months. Three patients with vertebral UF PB-DLBCL underwent early vertebroplasty without complications. The most common site involved was the vertebral column. Most patients with UF PB-DLBCL achieved complete remission (CR), whereas no patients with MF PB-DLBCL achieved CR.
CONCLUSION
PB-DLBCL is rare in adult Jordanian patients. UF PB-DLBCL is more common than MF PB-DLBCL. Patients with UF PB-DLBCL had a good prognosis. Patients with MF PB-DLBCL had a high international prognostic index score, risk of CNSR and short survival time.
背景
原发性骨弥漫性大B细胞淋巴瘤（PB-DLBCL）是一种罕见的结外淋巴瘤。本研究旨在探讨约旦成年PB-DLBCL患者的临床特征、预后、治疗方式及中枢神经系统复发（CNSR）风险。
方法
这项回顾性研究纳入了2002年至2021年间在我院诊断为PB-DLBCL并接受治疗的年龄大于16岁的患者。从医院数据系统中提取临床特征、治疗方式、预后和CNSR事件并进行分析。根据受累骨部位的数量将患者分为单灶性（UF）和多灶性（MF）PB-DLBCL组。仅一个部位受累定义为UF，而两个或更多部位受累定义为MF。
结果
共有12例患者被诊断为PB-DLBCL。他们的中位年龄为47.5岁（范围17 - 80岁）。男女比例为1:1。UF PB-DLBCL组有8例患者，MF PB-DLBCL组有4例患者。所有患者均接受了利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松龙治疗。在UF PB-DLBCL组中，男女比例为5:3，中位年龄为41岁，随访时间为9 - 135（平均83.3）个月。在MF PB-DLBCL组中，男女比例为1:3，中位年龄为51.5岁，生存时间为3 - 11（平均7）个月。3例椎体UF PB-DLBCL患者早期接受了椎体成形术，无并发症发生。最常受累的部位是脊柱。大多数UF PB-DLBCL患者实现了完全缓解（CR），而MF PB-DLBCL患者无一例实现CR。
结论
PB-DLBCL在约旦成年患者中罕见。UF PB-DLBCL比MF PB-DLBCL更常见。UF PB-DLBCL患者预后良好。MF PB-DLBCL患者国际预后指数评分高、CNSR风险高且生存时间短。
Zotero 插件